Skip to content
Afamitresgene Autoleucel & Vorasidenib episode artwork

Aug 8, 2024 12 min

Afamitresgene Autoleucel & Vorasidenib

from OncoPharm Hosted by John Bossaer

A new cellular therapy is approved for synovial sarcoma and the anticipated approval has occurred for the dual IDH1/IDH2 inhibitor, vorasidenib.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Afamitresgene Autoleucel & Vorasidenib

0:00 12:29

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OncoPharm?

This episode is 12 minutes long.

When was this OncoPharm episode published?

This episode was published on August 8, 2024.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.